The Cooper Companies, Inc. (NASDAQ:COO) Position Raised by Brown Brothers Harriman & Co.

Brown Brothers Harriman & Co. lifted its position in shares of The Cooper Companies, Inc. (NASDAQ:COO) by 227.2% in the 4th quarter, according to its most recent disclosure with the SEC. The fund owned 1,371 shares of the medical device company’s stock after acquiring an additional 952 shares during the period. Brown Brothers Harriman & Co.’s holdings in Cooper Companies were worth $126,000 as of its most recent filing with the SEC.

A number of other large investors have also modified their holdings of the company. Norges Bank bought a new position in Cooper Companies in the 4th quarter worth about $217,906,000. Raymond James Financial Inc. bought a new position in Cooper Companies in the 4th quarter worth approximately $64,826,000. Victory Capital Management Inc. increased its position in Cooper Companies by 14.6% in the 4th quarter. Victory Capital Management Inc. now owns 4,525,018 shares of the medical device company’s stock valued at $415,985,000 after acquiring an additional 574,899 shares during the period. JPMorgan Chase & Co. raised its stake in Cooper Companies by 13.2% during the 3rd quarter. JPMorgan Chase & Co. now owns 4,930,022 shares of the medical device company’s stock valued at $543,979,000 after acquiring an additional 573,908 shares in the last quarter. Finally, Wealthfront Advisers LLC raised its stake in Cooper Companies by 4,594.1% during the 4th quarter. Wealthfront Advisers LLC now owns 569,812 shares of the medical device company’s stock valued at $52,383,000 after acquiring an additional 557,673 shares in the last quarter. Institutional investors and hedge funds own 24.39% of the company’s stock.

Analyst Ratings Changes

A number of research analysts have recently commented on the company. Stifel Nicolaus lowered their price target on Cooper Companies from $115.00 to $105.00 and set a “buy” rating on the stock in a report on Friday, March 7th. Citigroup dropped their price target on shares of Cooper Companies from $115.00 to $110.00 and set a “buy” rating on the stock in a research report on Friday, March 7th. JPMorgan Chase & Co. decreased their price objective on shares of Cooper Companies from $120.00 to $110.00 and set an “overweight” rating for the company in a report on Friday, March 7th. BNP Paribas raised Cooper Companies to a “hold” rating in a report on Thursday, March 13th. Finally, Morgan Stanley decreased their price target on Cooper Companies from $104.00 to $102.00 and set an “equal weight” rating for the company in a research note on Friday, December 6th. Four analysts have rated the stock with a hold rating and seven have assigned a buy rating to the stock. According to MarketBeat, Cooper Companies presently has a consensus rating of “Moderate Buy” and an average target price of $110.25.

Cooper Companies Price Performance

Shares of NASDAQ:COO opened at $81.27 on Wednesday. The company has a market capitalization of $16.25 billion, a PE ratio of 41.68, a price-to-earnings-growth ratio of 2.25 and a beta of 1.02. The company has a debt-to-equity ratio of 0.32, a quick ratio of 1.12 and a current ratio of 1.91. The stock has a fifty day moving average of $88.87 and a 200-day moving average of $96.83. The Cooper Companies, Inc. has a one year low of $77.05 and a one year high of $112.38.

Cooper Companies (NASDAQ:COO) last announced its earnings results on Thursday, March 6th. The medical device company reported $0.92 EPS for the quarter, meeting the consensus estimate of $0.92. The business had revenue of $964.70 million during the quarter, compared to the consensus estimate of $981.25 million. Cooper Companies had a return on equity of 9.38% and a net margin of 10.07%. As a group, equities analysts anticipate that The Cooper Companies, Inc. will post 3.98 EPS for the current fiscal year.

Cooper Companies Company Profile

The Cooper Companies, Inc, together with its subsidiaries, develops, manufactures, and markets contact lens wearers. The company operates in two segments, CooperVision and CooperSurgical. The CooperVision segment provides spherical lense, including lenses that correct near and farsightedness; and toric and multifocal lenses comprising lenses correcting vision challenges, such as astigmatism, presbyopia, and myopia in the Americas, Europe, Middle East, Africa, and Asia Pacific.